The CRUSADE Bleeding Score provides clinicians with an objective metric to quantify a patient's risk of developing a life-threatening hemorrhage while receiving treatment for an acute coronary syndrome.
The Balancing Act
Treating a heart attack is inherently dangerous. The fundamental treatment involves paralyzing the body's clotting system using antiplatelets and anticoagulants. If a patient is at an extraordinarily high baseline risk for bleeding (e.g., they have kidney failure and low baseline hematocrit), the physician may choose less aggressive blood thinners, avoid certain invasive procedures, or adjust dosing strictly.
Sum of points derived from baseline hematocrit, CrCl, HR, SBP, sex, and history of vascular disease/diabetes/heart failure.
Key Factors
The score relies heavily on renal function (Creatinine Clearance). The kidneys clear many of the blood thinners used in cardiology. If the kidneys are failing, the drugs build up to toxic, bleeding-inducing levels in the blood. Baseline anemia (low hematocrit) and female sex are also significant independent risk factors.